← All Dossiers
Syndicate Bio — Seed
In Conversation Fund: StoryHouse Fund II
Dossier generated 2026-05-27 by /deal-dossier  ·  Deal record: recXKRVnv24jUNf2T  ·  Source: Airtable appjxAR3LPe3fkHOp

One-Liner & Thesis

A biotech platform driving genomic and precision medicine initiatives across the world's most diverse regions to enable drug discovery. Syndicate Bio operates in Biotech, Genomics; this dossier captures the Seed we participated in.

via StoryHouse Fund II, in a $3M round.

Deal Box

Round Size
$3M
Fund
StoryHouse Fund II
Funding Round
Seed

Company Snapshot

Sector
Biotech, Genomics
Location
Lagos, Nigeria
Year Founded
2023-03-01
Total Raised
$1.2M
Website
www.syndicate.bio
Status
Private

Founders

Estelle Dogbo
Founder/team member at Syndicate Bio.
LinkedIn
Jumi Popoola
Founder/team member at Syndicate Bio.
LinkedIn
Abasi Ene-Obong
Nigerian-born biomedical scientist and entrepreneur with deep global healthcare experience. Holds a PhD in Cancer Biology, an MSc in Human Molecular Genetics, and has worked as a research scientist, management consultant, and biotech builder; previously co-founder and CEO of 54gene, where he helped build one of the largest genomic biobanks focused on African genetic diversity, and now leads Syndicate Bio to build the world’s richest and most diverse human health datasets using AI/ML to advance inclusive discovery and precision medicine globally.
LinkedIn abasi@syndicate.bio

Latest Meeting Notes

2026-05-26 — Deal Call Notes - 2026-05-26

RAW NOTES: Syndicate Bio Business Model Overview • Building integrated precision medicine infrastructure for Africa • Three interconnected business units: • Clinical genomics testing • Precision therapeutics (drug licensing) • Data and IP licensing • Core thesis: 20-year drug launch delay from US to Africa creates opportunity • Most drugs arriv…

Source: Meeting Notes recvQRbvQ3yHulO4y
StoryHouse Ventures · Private · Generated 2026-05-27 05:00 UTC